Rigel Pharmaceutical (RIGL)
Trading: HOLD @ $2.4
Signal Strength: STRONG
Rigel Pharmaceutical (NASDAQ:RIGL) currently has positive MACD of 0.0317. Currently the signal line is greater than the MACD line signalling a bullish movement.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement
Moving Average Convergence/Divergence (MACD) is an indicator that shows the relationship between two moving averages. It is calculated as a difference between the fast and slow moving averages. The historically popular is the difference between a securities 26-day and 12-day Exponential Moving Averages (EMA).
Calculation:: Moving Average Convergence Divergence (MACD);
1) MACD Line: (12-day EMA - 26-day EMA);
2) Signal Line: 9-day EMA of MACD Line;
3) MACD Histogram: MACD Line - Signal Line;
PROFILE: Rigel Pharmaceutical (RIGL)
Stock Exchange: NASDAQ
Company: Rigel Pharmaceutical
Ticker Codes: | RIGL | NASDAQ:RIGL |
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.
|CPSI Computer Programs||33||14.5||741,564||0.66||BULLISH|
|CLDX Celldex Therapeutics||5.86||13.3||979,825||0.74||BULLISH|
|CRBP Corbus Pharma||8.95||10||2,875,687||0.13||BULLISH|
|OXFD Oxford Immunotec||16.89||9.5||415,732||0.18||BULLISH|
|MNTA Momenta Pharma||13.68||8.9||764,342||0.2||BULLISH|
|ADRO Aduro Biotech||3.99||8.4||1,151,038||0.08||BULLISH|
|ENTA Enanta Pharmaceutica||103.15||6.3||600,654||2.18||BULLISH|
|SSNC Ss&C Technologies||59.86||6.2||5,096,625||0.67||BULLISH|